Navigation Links
InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
Date:5/28/2009

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT.

Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively).

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and me
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
4. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
5. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
10. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
11. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... Obispo, CA (PRWEB) August 21, 2014 ... of Current Pedorthics, a bi-monthly publication of the Pedorthic Footcare ... of pedorthics. , Bunion Bootie is ... alternative solution for bunion sufferers and their pain. It is ... in nearly any shoe to eliminate the friction and rubbing ...
(Date:8/21/2014)... 21, 2014 According to a recent ... Ophthalmology, environmental factors may outweigh genetics in the development and ... of the world’s population is nearsighted, and this study provides ... “This is an important finding in the field of ophthalmology,” ... are we finding better ways to treat ophthalmological conditions ...
(Date:8/21/2014)... 21, 2014 Beverly Hills Medical Center of ... to offer patients TearLab, a new diagnostic option for measuring ... eye syndrome. , “ TearLab is a revolutionary new ... can accurately measure the amount of tears a patient produces ... Dr. Ghassan Zein, Medical Director at the Kuwait medical center. ...
(Date:8/21/2014)... Beverly Hills, CA (PRWEB) August 21, 2014 ... for your overall health. Juice cleanses offer clearer skin, more ... overall immune function. Pearl Recovery Retreat, a wellness center in ... programs right from the comfort of their recovery room. ... options to get them well again following surgery in our ...
Breaking Medicine News(10 mins):Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3
... Corporation,("WorldHeart", Nasdaq: WHRT ), a pioneer in ... Alexander ("Alex") Martin as,President and CEO. Mr. Martin ... Mr. Martin joins WorldHeart from Edwards Lifesciences where ... Vice President since,2004. Previously, Alex was with Cordis ...
... Site Uses Search to Improve Point-of-Care Decisions ... leader in enterprise search, recently published a ... Platform(TM) helps health-care practitioners deliver faster and ... The case study details Vivisimo,s application for ...
... cancer risk almost 6-fold, researchers find , , FRIDAY, Feb. ... mutations that appear to predict a significant increased risk ... to early diagnosis and treatment, the researchers said. In ... and 1,590 deaths, according to the U.S. National Cancer ...
... University at Buffalo researcher John Violanti, Ph.D., a specialist ... a study on suicide risk among returning veterans. The ... number of soldiers taking their own lives., Violanti currently ... quickly persons associate feelings of self-harm, as a way ...
... Feb. 6 Masimo Corporation (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, today announced that its management ... 21st Annual OC Growth Stock Conference at The Ritz-Carlton, ... 18, 2009, at 11:00 a.m. PT. A live audiocast ...
... Feb. 6 Optimal Reading Services Group, ... hospitals and radiology group practices, announced that its chief ... UBS Global Healthcare Services Conference on Monday, February 9, ... Hotel in New York City.Optimal leverages a deep pool ...
Cached Medicine News:Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3Health News:New Vivisimo Case Study Details Medical Search 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:Optimal Readings to Present at 2009 UBS Global Healthcare Services Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: